Sildenafil Tablet, Film Coated
Product Images NDC 71209-108

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71209-108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cadila Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cont-label-1000s-100mg (Cont Label 1000s 100mg)

Sildenafil tablets, USP 100 mg, film-coated oral tablets in a 1000 tablet package. The label shows storage instructions for controlled room temperature and cautions to keep out of reach of children. Manufactured by Cadila Pharmaceuticals Limited, India, with a barcode and lot number area.*

FDA Label Image

Cont-label-1000s-25mg (Cont Label 1000s 25mg)

Label for Sildenafil Tablets, USP 25 mg film-coated tablets. The label shows the dosage strength (25 mg), product name, a barcode, manufacturer information (Cadila Pharmaceuticals Limited, Ahmedabad, India), storage instructions, and a note indicating prescription-only use with a package size of 1000 tablets.*

FDA Label Image

Cont-label-1000s-50mg (Cont Label 1000s 50mg)

Packaging label for Sildenafil Tablets, USP 50 mg film-coated oral tablets manufactured by Cadila Pharmaceuticals Limited. The label states the product is prescription-only, contains 1000 tablets, and includes storage instructions and safety warnings. The NDC code is 71209-107-11.*

FDA Label Image

Cont-label-100s-100mg (Cont Label 100s 100mg)

Sildenafil tablets USP 100 mg film-coated oral tablets packaging label by Cadila Pharmaceuticals Limited. The label includes dosage strength (100 mg), quantity (100 tablets), and storage instructions. It displays NDC 71209-108-05 and manufacturer details from Ahmedabad, Gujarat, India, with a barcode and child-resistant container instructions.*

FDA Label Image

Cont-label-100s-25mg (Cont Label 100s 25mg)

Sildenafil Tablets USP 25 mg film-coated tablets label from Cadila Pharmaceuticals Limited. The label includes dosing and storage instructions, states the package contains 100 tablets, and displays the NDC code 71209-106-05. It specifies child-resistant packaging and includes a barcode on the right side of the label.*

FDA Label Image

Cont-label-100s-50mg.jpg (Cont Label 100s 50mg)

Sildenafil Tablets, USP 50 mg film-coated tablets label from Cadila Pharmaceuticals Limited. The label includes storage instructions, dosage form, quantity of 100 tablets, and NDC 71209-107-05. It states Rx only, packaging in a child-resistant container, and space for serialized datamatrix code and batch coding.*

FDA Label Image

Cont-label-30s-100mg (Cont Label 30s 100mg)

Packaging label for Sildenafil Tablets USP 100 mg film-coated tablets by Cadila Pharmaceuticals Limited. The label includes a 30-tablet count and states prescription use only, along with storage instructions and manufacturer details from Gujarat, India. A barcode and space for serialization and batch coding are also visible.*

FDA Label Image

Cont-label-30s-25mg (Cont Label 30s 25mg)

Label for Sildenafil Tablets, USP 25 mg by Cadila Pharmaceuticals Limited. The film-coated oral tablets come in a package of 30. The label includes storage instructions, dosage and use directions reference, manufacturer details, and a barcode.*

FDA Label Image

Cont-label-30s-50mg (Cont Label 30s 50mg)

Label for Sildenafil Tablets USP 50 mg by Cadila Pharmaceuticals Limited. The label indicates a 30-tablet count and prescription only status, with dosing information and storage instructions. It also provides manufacturer details and an NDC number 71209-107-01, alongside a barcode and space for additional coding.*

FDA Label Image

Fig-1 (Fig 1)

A line graph depicting changes in systolic blood pressure (mmHg) over 24 hours post-dose. It compares two groups: one receiving Sildenafil 100 mg and a placebo group. The x-axis shows time in hours, and the y-axis shows systolic blood pressure change. Data points are marked and connected by lines for each group.*

FDA Label Image

Fig-2 (Fig 2)

A line graph comparing the change in mean arterial pressure (MAP) over time after a single dose between Doxazosin and Sildenafil 25 mg. The x-axis represents time post-dose in hours, and the y-axis represents the change in MAP in mmHg. Doxazosin shows a different trend compared to Sildenafil during the 8-hour observation period.*

FDA Label Image

Fig-3 (Fig 3)

A line chart comparing change in an unspecified measurement over time (in minutes) between two groups: one receiving Doxazosin plus placebo and the other receiving Doxazosin plus Sildenafil 50 mg. The x-axis shows time points up to 8,000 minutes, and the y-axis shows percentage change ranging from -50% to 40%.*

FDA Label Image

Fig-4 (Fig 4)

A line graph comparing the effects of Doxazosin combined with Sildenafil 100 mg versus Doxazosin with placebo over time after dosing. The y-axis represents measurements in mmHg and the x-axis shows time in hours post-dosing, displaying two lines with data points for each treatment group from 0 to 8 hours.*

FDA Label Image

Fig-5 (Fig 5)

A pharmacokinetic line graph showing plasma concentration (ng/mL) over time (hours) post dose for a commercial tablet of Sildenafil. The graph illustrates the drug concentration peaking shortly after administration and gradually decreasing back toward baseline by 24 hours.*

FDA Label Image

Fig-6-1 (Fig 6 1)

A bar chart depicting percentages of patients at endpoint across different baseline scores ranging from 0 to 5. The chart includes multiple grouped bars for each baseline score, reflecting various categories labeled 0 through 5, showing a trend of increasing percentage values, particularly for category 5 at higher baseline scores.*

FDA Label Image

Fig-6-2 (Fig 6 2)

A bar chart titled 'Effect of Placebo on Maintenance of Erection by Baseline Score.' It displays the percentage of patients as endpoints across baseline scores from 0 to 5, with multiple bar categories labeled from 0 to 5 representing data groups or intervals.*

FDA Label Image

Fig-7 (Fig 7)

A bar graph comparing the percentage of patients reporting improvement across four groups: Placebo, sildenafil citrate 25 mg, sildenafil citrate 50 mg, and sildenafil citrate 100 mg. The percentages increase progressively from placebo to the highest dose of sildenafil citrate.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Sildenafil, showing its molecular composition including rings and functional groups characteristic to the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.